Advertisement

Uncommon hereditary gynaecological tumour syndromes: pathological features in tumours that may predict risk for a germline mutation

Published:January 18, 2018DOI:https://doi.org/10.1016/j.pathol.2017.10.009

      Summary

      The most common hereditary gynaecological tumour syndromes are hereditary breast and ovarian cancer syndrome and Lynch syndrome. However, pathologists also may encounter gynaecological tumours in women with rare hereditary syndromes. Many of these tumours exhibit distinctive gross and microscopic features that are associated with a risk for an inherited gene mutation. The sensitivity and specificity of these tumour pathology features for predicting an inherited mutation vary depending on the syndrome. By recognising these tumour features, pathologists may potentially contribute to the diagnosis of an unsuspected syndrome by recommending referral of the patient for formal risk assessment by genetic counselling. Patients additionally benefit from diagnosis of an inherited syndrome because many also carry a lifetime risk for developing primary malignancies outside of the gynaecological tract. Early diagnosis of an inherited syndrome permits early screening, detection, and management of additional malignancies associated with the syndrome. This review highlights these rare syndromes and their tumour pathology, including Peutz–Jeghers syndrome (gastric type mucinous carcinoma of the cervix; ovarian sex cord tumour with annular tubules); hereditary leiomyoma renal cell carcinoma syndrome (uterine leiomyoma); tuberous sclerosis complex (uterine PEComa; uterine lymphangioleiomyomatosis); DICER1 syndrome (ovarian Sertoli–Leydig cell tumour; cervical embryonal rhabdomyosarcoma); rhabdoid tumour predisposition syndrome 2 (small cell carcinoma of the ovary, hypercalcaemic type); Cowden syndrome (endometrial endometrioid adenocarcinoma); naevoid basal cell carcinoma syndrome (ovarian fibroma); and Von Hippel–Lindau syndrome (clear cell papillary cystadenoma of the broad ligament).

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Pathology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hemminki A.
        • Markie D.
        • Tomlinson I.
        • et al.
        A serine/threonine kinase gene defective in Peutz-Jeghers syndrome.
        Nature. 1998; 391: 184-187
        • Jenne D.E.
        • Reimann H.
        • Nezu J.
        • et al.
        Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase.
        Nat Genet. 1998; 18: 38-43
        • Peutz J.L.A.
        Very remarkable case of familial polyposis of mucous membrane of intestinal tract and nasopharynx accompanied by peculiar pigmentations of skin and mucous membrane.
        Nederl Maandschr Geneesk. 1921; 10: 134-146
        • Jeghers H.
        • Mc K.V.
        • Katz K.H.
        Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance.
        N Engl J Med. 1949; 241: 1031-1036
        • Bruwer A.
        • Bargen J.A.
        Surface pigmentation and generalized intestinal polyposis (Peutz-Jeghers syndrome).
        Proc Staff Meet Mayo Clin. 1954; 29: 168-171
        • Giardiello F.M.
        • Trimbath J.D.
        Peutz-Jeghers syndrome and management recommendations.
        Clin Gastroenterol Hepatol. 2006; 4: 408-415
        • Beggs A.D.
        • Latchford A.R.
        • Vasen H.F.
        • et al.
        Peutz-Jeghers syndrome: a systematic review and recommendations for management.
        Gut. 2010; 59: 975-986
        • Aretz S.
        • Stienen D.
        • Uhlhaas S.
        • et al.
        High proportion of large genomic STK11 deletions in Peutz-Jeghers syndrome.
        Hum Mutat. 2005; 26: 513-519
        • Giardiello F.M.
        • Brensinger J.D.
        • Tersmette A.C.
        • et al.
        Very high risk of cancer in familial Peutz-Jeghers syndrome.
        Gastroenterology. 2000; 119: 1447-1453
        • National Comprehensive Cancer Network
        NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: colorectal. Version 2.
        2016
        • Ferry J.A.
        • Young R.H.
        • Engel G.
        • et al.
        Oxyphilic Sertoli cell tumor of the ovary: a report of three cases, two in patients with the Peutz-Jeghers syndrome.
        Int J Gynecol Pathol. 1994; 13: 259-266
        • Gilks C.B.
        • Young R.H.
        • Aguirre P.
        • et al.
        Adenoma malignum (minimal deviation adenocarcinoma) of the uterine cervix. A clinicopathological and immunohistochemical analysis of 26 cases.
        Am J Surg Pathol. 1989; 13: 717-729
        • Chen K.T.
        Female genital tract tumors in Peutz-Jeghers syndrome.
        Hum Pathol. 1986; 17: 858-861
        • Kuragaki C.
        • Enomoto T.
        • Ueno Y.
        • et al.
        Mutations in the STK11 gene characterize minimal deviation adenocarcinoma of the uterine cervix.
        Lab Invest. 2003; 83: 35-45
        • Young R.H.
        • Welch W.R.
        • Dickersin G.R.
        • et al.
        Ovarian sex cord tumor with annular tubules: review of 74 cases including 27 with Peutz-Jeghers syndrome and four with adenoma malignum of the cervix.
        Cancer. 1982; 50: 1384-1402
        • Kojima A.
        • Mikami Y.
        • Sudo T.
        • et al.
        Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix.
        Am J Surg Pathol. 2007; 31: 664-672
        • Kondo T.
        • Hashi A.
        • Murata S.
        • et al.
        Endocervical adenocarcinomas associated with lobular endocervical glandular hyperplasia: a report of four cases with histochemical and immunohistochemical analyses.
        Mod Pathol. 2005; 18: 1199-1210
        • Mikami Y.
        • Kiyokawa T.
        • Hata S.
        • et al.
        Gastrointestinal immunophenotype in adenocarcinomas of the uterine cervix and related glandular lesions: a possible link between lobular endocervical glandular hyperplasia/pyloric gland metaplasia and 'adenoma malignum'.
        Mod Pathol. 2004; 17: 962-972
        • Nara M.
        • Hashi A.
        • Murata S.
        • et al.
        Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection.
        Gynecol Oncol. 2007; 106: 289-298
        • Nishio S.
        • Tsuda H.
        • Fujiyoshi N.
        • et al.
        Clinicopathological significance of cervical adenocarcinoma associated with lobular endocervical glandular hyperplasia.
        Pathol Res Pract. 2009; 205: 331-337
        • Xu J.Y.
        • Hashi A.
        • Kondo T.
        • et al.
        Absence of human papillomavirus infection in minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia.
        Int J Gynecol Pathol. 2005; 24: 296-302
        • Hirasawa A.
        • Akahane T.
        • Tsuruta T.
        • et al.
        Lobular endocervical glandular hyperplasia and peritoneal pigmentation associated with Peutz-Jeghers syndrome due to a germline mutation of STK11.
        Ann Oncol. 2012; 23: 2990-2992
        • Matsubara A.
        • Sekine S.
        • Ogawa R.
        • et al.
        Lobular endocervical glandular hyperplasia is a neoplastic entity with frequent activating GNAS mutations.
        Am J Surg Pathol. 2014; 38: 370-376
        • Talia K.L.
        • Stewart C.J.R.
        • Howitt B.E.
        • et al.
        HPV-negative gastric type adenocarcinoma in situ of the cervix: a spectrum of rare lesions exhibiting gastric and intestinal differentiation.
        Am J Surg Pathol. 2017; 41: 1023-1033
        • Park K.J.
        • Kiyokawa T.
        • Soslow R.A.
        • et al.
        Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus.
        Am J Surg Pathol. 2011; 35: 633-646
        • Kusanagi Y.
        • Kojima A.
        • Mikami Y.
        • et al.
        Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype.
        Am J Pathol. 2010; 177: 2169-2175
        • Wada T.
        • Ohishi Y.
        • Kaku T.
        • et al.
        Endocervical adenocarcinoma with morphologic features of both usual and gastric types: clinicopathologic and immunohistochemical analyses and high-risk HPV detection by in situ hybridization.
        Am J Surg Pathol. 2017; 41: 696-705
        • Ishihara K.
        • Kurihara M.
        • Goso Y.
        • et al.
        Peripheral alpha-linked N-acetylglucosamine on the carbohydrate moiety of mucin derived from mammalian gastric gland mucous cells: epitope recognized by a newly characterized monoclonal antibody.
        Biochem J. 1996; 318: 409-416
        • Ichimura T.
        • Koizumi T.
        • Tateiwa H.
        • et al.
        Immunohistochemical expression of gastric mucin and p53 in minimal deviation adenocarcinoma of the uterine cervix.
        Int J Gynecol Pathol. 2001; 20: 220-226
        • Ishii K.
        • Hosaka N.
        • Toki T.
        • et al.
        A new view of the so-called adenoma malignum of the uterine cervix.
        Virchows Arch. 1998; 432: 315-322
        • Utsugi K.
        • Hirai Y.
        • Takeshima N.
        • et al.
        Utility of the monoclonal antibody HIK1083 in the diagnosis of adenoma malignum of the uterine cervix.
        Gynecol Oncol. 1999; 75: 345-348
        • Zhao S.
        • Hayasaka T.
        • Osakabe M.
        • et al.
        Mucin expression in nonneoplastic and neoplastic glandular epithelia of the uterine cervix.
        Int J Gynecol Pathol. 2003; 22: 393-397
        • Bartman A.E.
        • Buisine M.P.
        • Aubert J.P.
        • et al.
        The MUC6 secretory mucin gene is expressed in a wide variety of epithelial tissues.
        J Pathol. 1998; 186: 398-405
        • Toribara N.W.
        • Roberton A.M.
        • Ho S.B.
        • et al.
        Human gastric mucin. Identification of a unique species by expression cloning.
        J Biol Chem. 1993; 268: 5879-5885
        • Carleton C.
        • Hoang L.
        • Sah S.
        • et al.
        A detailed immunohistochemical analysis of a large series of cervical and vaginal gastric-type adenocarcinomas.
        Am J Surg Pathol. 2016; 40: 636-644
        • Anjarwalla S.
        • Rollason T.P.
        • Rooney N.
        • et al.
        Atypical mucinous metaplasia and intraepithelial neoplasia of the female genital tract – a case report and review of the literature.
        Int J Gynecol Cancer. 2007; 17: 1147-1150
        • Mikami Y.
        • Kiyokawa T.
        • Sasajima Y.
        • et al.
        Reappraisal of synchronous and multifocal mucinous lesions of the female genital tract: a close association with gastric metaplasia.
        Histopathology. 2009; 54: 184-191
        • Nagahama K.
        • Yamanaka S.
        • Nakayama T.
        • et al.
        A case of synchronous mucinous metaplasia and neoplasia of the female genital tract without an STK11 or KRAS mutation.
        Gynecol Oncol Case Rep. 2013; 5: 4-5
        • Scully R.E.
        Sex cord tumor with annular tubules a distinctive ovarian tumor of the Peutz-Jeghers syndrome.
        Cancer. 1970; 25: 1107-1121
        • Lewis T.C.
        • Short C.
        A Latin dictionary.
        Clarendon Press, Oxford1879
      1. Merriam-Webster. Definition of antipodal. https://www.merriam-webster.com/dictionary/antipodal.

        • Deavers M.T.
        • Malpica A.
        • Liu J.
        • et al.
        Ovarian sex cord-stromal tumors: an immunohistochemical study including a comparison of calretinin and inhibin.
        Mod Pathol. 2003; 16: 584-590
        • Kommoss F.
        • Oliva E.
        • Bhan A.K.
        • et al.
        Inhibin expression in ovarian tumors and tumor-like lesions: an immunohistochemical study.
        Mod Pathol. 1998; 11: 656-664
        • McCluggage W.G.
        • Maxwell P.
        Immunohistochemical staining for calretinin is useful in the diagnosis of ovarian sex cord-stromal tumours.
        Histopathology. 2001; 38: 403-408
        • Al-Agha O.M.
        • Huwait H.F.
        • Chow C.
        • et al.
        FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary.
        Am J Surg Pathol. 2011; 35: 484-494
        • Lele S.M.
        • Sawh R.N.
        • Zaharopoulos P.
        • et al.
        Malignant ovarian sex cord tumor with annular tubules in a patient with Peutz-Jeghers syndrome: a case report.
        Mod Pathol. 2000; 13: 466-470
        • Tomlinson I.P.
        • Alam N.A.
        • Rowan A.J.
        • et al.
        Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.
        Nat Genet. 2002; 30: 406-410
        • Alam N.A.
        • Olpin S.
        • Leigh I.M.
        Fumarate hydratase mutations and predisposition to cutaneous leiomyomas, uterine leiomyomas and renal cancer.
        Br J Dermatol. 2005; 153: 11-17
        • Toro J.R.
        • Nickerson M.L.
        • Wei M.H.
        • et al.
        Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America.
        Am J Hum Genet. 2003; 73: 95-106
        • Kiuru M.
        • Launonen V.
        • Hietala M.
        • et al.
        Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology.
        Am J Pathol. 2001; 159: 825-829
        • Linehan W.M.
        • Rouault T.A.
        Molecular pathways: fumarate hydratase-deficient kidney cancer – targeting the Warburg effect in cancer.
        Clin Cancer Res. 2013; 19: 3345-3352
        • Sudarshan S.
        • Sourbier C.
        • Kong H.S.
        • et al.
        Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species.
        Mol Cell Biol. 2009; 29: 4080-4090
        • Chen Y.B.
        • Brannon A.R.
        • Toubaji A.
        • et al.
        Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry.
        Am J Surg Pathol. 2014; 38: 627-637
        • Smith S.C.
        • Trpkov K.
        • Chen Y.B.
        • et al.
        Tubulocystic carcinoma of the kidney with poorly differentiated foci: a frequent morphologic pattern of fumarate hydratase-deficient renal cell carcinoma.
        Am J Surg Pathol. 2016; 40: 1457-1472
        • Merino M.J.
        • Torres-Cabala C.
        • Pinto P.
        • et al.
        The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome.
        Am J Surg Pathol. 2007; 31: 1578-1585
        • Menko F.H.
        • Maher E.R.
        • Schmidt L.S.
        • et al.
        Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment.
        Fam Cancer. 2014; 13: 637-644
        • Reyes C.
        • Karamurzin Y.
        • Frizzell N.
        • et al.
        Uterine smooth muscle tumors with features suggesting fumarate hydratase aberration: detailed morphologic analysis and correlation with S-(2-succino)-cysteine immunohistochemistry.
        Mod Pathol. 2014; 27: 1020-1027
        • Alam N.A.
        • Barclay E.
        • Rowan A.J.
        • et al.
        Clinical features of multiple cutaneous and uterine leiomyomatosis: an underdiagnosed tumor syndrome.
        Arch Dermatol. 2005; 141: 199-206
        • Harrison W.J.
        • Andrici J.
        • Maclean F.
        • et al.
        Fumarate Hydratase-deficient uterine leiomyomas occur in both the syndromic and sporadic settings.
        Am J Surg Pathol. 2016; 40: 599-607
        • Wei M.H.
        • Toure O.
        • Glenn G.M.
        • et al.
        Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer.
        J Med Genet. 2006; 43: 18-27
        • Sanz-Ortega J.
        • Vocke C.
        • Stratton P.
        • et al.
        Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
        Am J Surg Pathol. 2013; 37: 74-80
        • Joseph N.M.
        • Solomon D.A.
        • Frizzell N.
        • et al.
        Morphology and immunohistochemistry for 2SC and FH aid in detection of fumarate hydratase gene aberrations in uterine leiomyomas from young patients.
        Am J Surg Pathol. 2015; 39: 1529-1539
        • Garg K.
        • Tickoo S.K.
        • Soslow R.A.
        • et al.
        Morphologic features of uterine leiomyomas associated with hereditary leiomyomatosis and renal cell carcinoma syndrome: a case report.
        Am J Surg Pathol. 2011; 35: 1235-1237
        • Miettinen M.
        • Felisiak-Golabek A.
        • Wasag B.
        • et al.
        Fumarase-deficient uterine leiomyomas: an immunohistochemical, molecular genetic, and clinicopathologic study of 86 cases.
        Am J Surg Pathol. 2016; 40: 1661-1669
        • Merino M.
        • Stratton P.
        • Linehan M.W.
        • Lara-Otero K.
        Fumarate Hydratase assist to recognize smooth muscle tumors associated with hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC).
        Mod Pathol. 2014; 27
        • Bennett J.A.
        • Weigelt B.
        • Chiang S.
        • et al.
        Leiomyoma with bizarre nuclei: a morphological, immunohistochemical and molecular analysis of 31 cases.
        Mod Pathol. 2017; 30: 1476-1488
        • Buelow B.
        • Cohen J.
        • Nagymanyoki Z.
        • et al.
        Immunohistochemistry for 2-Succinocysteine (2SC) and Fumarate Hydratase (FH) in cutaneous leiomyomas may aid in identification of patients with HLRCC (hereditary leiomyomatosis and renal cell carcinoma syndrome).
        Am J Surg Pathol. 2016; 40: 982-988
        • Bardella C.
        • El-Bahrawy M.
        • Frizzell N.
        • et al.
        Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status.
        J Pathol. 2011; 225: 4-11
        • van Slegtenhorst M.
        • de Hoogt R.
        • Hermans C.
        • et al.
        Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34.
        Science. 1997; 277: 805-808
        • Northrup H.
        • Krueger D.A.
        • International Tuberous Sclerosis Complex Consensus Group
        Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference.
        Pediatr Neurol. 2013; 49: 243-254
        • Tee A.R.
        • Fingar D.C.
        • Manning B.D.
        • et al.
        Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
        Proc Natl Acad Sci USA. 2002; 99: 13571-13576
        • Agaram N.P.
        • Sung Y.S.
        • Zhang L.
        • et al.
        Dichotomy of genetic abnormalities in PEComas with therapeutic implications.
        Am J Surg Pathol. 2015; 39: 813-825
        • Dickson M.A.
        • Schwartz G.K.
        • Antonescu C.R.
        • et al.
        Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.
        Int J Cancer. 2013; 132: 1711-1717
        • Italiano A.
        • Delcambre C.
        • Hostein I.
        • et al.
        Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa.
        Ann Oncol. 2010; 21: 1135-1137
        • Wagner A.J.
        • Malinowska-Kolodziej I.
        • Morgan J.A.
        • et al.
        Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
        J Clin Oncol. 2010; 28: 835-840
        • Northrup H.
        • Koenig M.K.
        • Pearson D.A.
        • et al.
        Tuberous sclerosis complex.
        in: Pagon R.A. Adam M.P. Ardinger H.H. GeneReviews. University of Washington, Seattle2017
        • Krueger D.A.
        • Northrup H.
        • International Tuberous Sclerosis Complex Consensus Group
        Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference.
        Pediatr Neurol. 2013; 49: 255-265
        • Jones A.C.
        • Daniells C.E.
        • Snell R.G.
        • et al.
        Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis.
        Hum Mol Genet. 1997; 6: 2155-2161
        • Jones A.C.
        • Shyamsundar M.M.
        • Thomas M.W.
        • et al.
        Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis.
        Am J Hum Genet. 1999; 64: 1305-1315
        • Dabora S.L.
        • Jozwiak S.
        • Franz D.N.
        • et al.
        Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.
        Am J Hum Genet. 2001; 68: 64-80
        • Kurman R.J.
        • Carcangiu M.L.
        • Herrington C.S.
        • Young R.H.
        WHO Classification of Tumors of the Female Reproductive Organs.
        IARC Press, Lyon, France2014
        • Hornick J.L.
        • Fletcher C.D.
        Sclerosing PEComa: clinicopathologic analysis of a distinctive variant with a predilection for the retroperitoneum.
        Am J Surg Pathol. 2008; 32: 493-501
        • Yamada Y.
        • Yamamoto H.
        • Ohishi Y.
        • et al.
        Sclerosing variant of perivascular epithelioid cell tumor in the female genital organs.
        Pathol Int. 2011; 61: 768-772
        • Rao Q.
        • Cheng L.
        • Xia Q.Y.
        • et al.
        Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (PEComas): a clinicopathological study emphasizing extrarenal PEComas.
        Histopathology. 2013; 62: 642-650
        • Martignoni G.
        • Bonetti F.
        • Chilosi M.
        • et al.
        Cathepsin K expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney.
        Mod Pathol. 2012; 25: 100-111
        • Schoolmeester J.K.
        • Howitt B.E.
        • Hirsch M.S.
        • et al.
        Perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: clinicopathologic and immunohistochemical characterization of 16 cases.
        Am J Surg Pathol. 2014; 38: 176-188
        • Schoolmeester J.K.
        • Dao L.N.
        • Sukov W.R.
        • et al.
        TFE3 translocation-associated perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: morphology, immunophenotype, differential diagnosis.
        Am J Surg Pathol. 2015; 39: 394-404
        • Folpe A.L.
        • Mentzel T.
        • Lehr H.A.
        • et al.
        Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature.
        Am J Surg Pathol. 2005; 29: 1558-1575
        • Fadare O.
        • Parkash V.
        • Yilmaz Y.
        • et al.
        Perivascular epithelioid cell tumor (PEComa) of the uterine cervix associated with intraabdominal “PEComatosis”: a clinicopathological study with comparative genomic hybridization analysis.
        World J Surg Oncol. 2004; 2: 35
        • Liang S.X.
        • Pearl M.
        • Liu J.
        • et al.
        “Malignant” uterine perivascular epithelioid cell tumor, pelvic lymph node lymphangioleiomyomatosis, and gynecological pecomatosis in a patient with tuberous sclerosis: a case report and review of the literature.
        Int J Gynecol Pathol. 2008; 27: 86-90
        • Froio E.
        • Piana S.
        • Cavazza A.
        • et al.
        Multifocal PEComa (PEComatosis) of the female genital tract associated with endometriosis, diffuse adenomyosis, and endometrial atypical hyperplasia.
        Int J Surg Pathol. 2008; 16: 443-446
        • Aydin H.
        • Magi-Galluzzi C.
        • Lane B.R.
        • et al.
        Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association.
        Am J Surg Pathol. 2009; 33: 289-297
        • Lim G.S.
        • Oliva E.
        The morphologic spectrum of uterine PEC-cell associated tumors in a patient with tuberous sclerosis.
        Int J Gynecol Pathol. 2011; 30: 121-128
        • Hayashi T.
        • Kumasaka T.
        • Mitani K.
        • et al.
        Prevalence of uterine and adnexal involvement in pulmonary lymphangioleiomyomatosis: a clinicopathologic study of 10 patients.
        Am J Surg Pathol. 2011; 35: 1776-1785
        • Schoolmeester J.K.
        • Park K.J.
        Incidental nodal lymphangioleiomyomatosis is not a harbinger of pulmonary lymphangioleiomyomatosis: a study of 19 cases with evaluation of diagnostic immunohistochemistry.
        Am J Surg Pathol. 2015; 39: 1404-1410
        • Rabban J.T.
        • Firetag B.
        • Sangoi A.R.
        • et al.
        Incidental pelvic and para-aortic lymph node lymphangioleiomyomatosis detected during surgical staging of pelvic cancer in women without symptomatic pulmonary lymphangioleiomyomatosis or tuberous sclerosis complex.
        Am J Surg Pathol. 2015; 39: 1015-1025
        • Cil A.P.
        • Haberal A.
        • Hucumenoglu S.
        • et al.
        Angiomyolipoma of the uterus associated with tuberous sclerosis: case report and review of the literature.
        Gynecol Oncol. 2004; 94: 593-596
        • Yaegashi H.
        • Moriya T.
        • Soeda S.
        • et al.
        Uterine angiomyolipoma: case report and review of the literature.
        Pathol Int. 2001; 51: 896-901
        • Foulkes W.D.
        • Priest J.R.
        • Duchaine T.F.
        DICER1: mutations, microRNAs and mechanisms.
        Nat Rev Cancer. 2014; 14: 662-672
        • Hill D.A.
        • Ivanovich J.
        • Priest J.R.
        • et al.
        DICER1 mutations in familial pleuropulmonary blastoma.
        Science. 2009; 325: 965
        • Anglesio M.S.
        • Wang Y.
        • Yang W.
        • et al.
        Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage.
        J Pathol. 2013; 229: 400-409
        • Heravi-Moussavi A.
        • Anglesio M.S.
        • Cheng S.W.
        • et al.
        Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.
        N Engl J Med. 2012; 366: 234-242
        • Wang Y.
        • Chen J.
        • Yang W.
        • et al.
        The oncogenic roles of DICER1 RNase IIIb domain mutations in ovarian Sertoli-Leydig cell tumors.
        Neoplasia. 2015; 17: 650-660
        • Kim J.
        • Field A.
        • Schultz K.A.P.
        • et al.
        The prevalence of DICER1 pathogenic variation in population databases.
        Int J Cancer. 2017; 141: 2030-2036
        • de Kock L.
        • Sabbaghian N.
        • Plourde F.
        • et al.
        Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations.
        Acta Neuropathol. 2014; 128: 111-122
        • Doros L.A.
        • Rossi C.T.
        • Yang J.
        • et al.
        DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma.
        Mod Pathol. 2014; 27: 1267-1280
        • de Kock L.
        • Terzic T.
        • McCluggage W.G.
        • et al.
        DICER1 mutations are consistently present in moderately and poorly differentiated Sertoli-Leydig cell tumors.
        Am J Surg Pathol. 2017; 41: 1178-1187
        • Pugh T.J.
        • Yu W.
        • Yang J.
        • et al.
        Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences.
        Oncogene. 2014; 33: 5295-5302
        • Seki M.
        • Yoshida K.
        • Shiraishi Y.
        • et al.
        Biallelic DICER1 mutations in sporadic pleuropulmonary blastoma.
        Cancer Res. 2014; 74: 2742-2749
        • Schultz K.A.
        • Harris A.
        • Williams G.M.
        • et al.
        Judicious DICER1 testing and surveillance imaging facilitates early diagnosis and cure of pleuropulmonary blastoma.
        Pediatr Blood Cancer. 2014; 61: 1695-1697
        • Stewart C.J.
        • Charles A.
        • Foulkes W.D.
        Gynecologic manifestations of the DICER1 syndrome.
        Surg Pathol Clin. 2016; 9: 227-241
        • Kurman R.J.
        • Carcangiu M.L.
        • Herrington C.S.
        • Young R.H.
        WHO Classification of Tumours of Female Reproductive Organs.
        International Agency for Research on Cancer, Lyon2014
        • Young R.H.
        • Scully R.E.
        Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases.
        Am J Surg Pathol. 1985; 9: 543-569
        • Prat J.
        • Young R.H.
        • Scully R.E.
        Ovarian Sertoli-Leydig cell tumors with heterologous elements. II. Cartilage and skeletal muscle: a clinicopathologic analysis of twelve cases.
        Cancer. 1982; 50: 2465-2475
        • Young R.H.
        • Prat J.
        • Scully R.E.
        Ovarian Sertoli-Leydig cell tumors with heterologous elements. I. Gastrointestinal epithelium and carcinoid: a clinicopathologic analysis of thirty-six cases.
        Cancer. 1982; 50: 2448-2456
        • Young R.H.
        • Scully R.E.
        Ovarian Sertoli-Leydig cell tumors with a retiform pattern: a problem in histopathologic diagnosis. A report of 25 cases.
        Am J Surg Pathol. 1983; 7: 755-771
        • Rabban J.T.
        • Zaloudek C.J.
        A practical approach to immunohistochemical diagnosis of ovarian germ cell tumours and sex cord-stromal tumours.
        Histopathology. 2013; 62: 71-88
        • Farinola M.A.
        • Gown A.M.
        • Judson K.
        • et al.
        Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors.
        Int J Gynecol Pathol. 2007; 26: 375-382
        • Zhao C.
        • Vinh T.N.
        • McManus K.
        • et al.
        Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors.
        Am J Surg Pathol. 2009; 33: 354-366
        • Oost E.E.
        • Charles A.
        • Choong C.S.
        • et al.
        Ovarian sex cord-stromal tumors in patients with probable or confirmed germline DICER1 mutations.
        Int J Gynecol Pathol. 2015; 34: 266-274
        • Conlon N.
        • Schultheis A.M.
        • Piscuoglio S.
        • et al.
        A survey of DICER1 hotspot mutations in ovarian and testicular sex cord-stromal tumors.
        Mod Pathol. 2015; 28: 1603-1612
        • Goulvent T.
        • Ray-Coquard I.
        • Borel S.
        • et al.
        DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: a GINECO Group study.
        Histopathology. 2016; 68: 279-285
        • Kim M.S.
        • Lee S.H.
        • Yoo N.J.
        • et al.
        DICER1 exons 25 and 26 mutations are rare in common human tumours besides Sertoli-Leydig cell tumour.
        Histopathology. 2013; 63: 436-438
        • Schultz K.A.
        • Pacheco M.C.
        • Yang J.
        • et al.
        Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and DICER1 mutations: a report from the International Pleuropulmonary Blastoma Registry.
        Gynecol Oncol. 2011; 122: 246-250
        • Witkowski L.
        • Mattina J.
        • Schonberger S.
        • et al.
        DICER1 hotspot mutations in non-epithelial gonadal tumours.
        Br J Cancer. 2013; 109: 2744-2750
        • Zou Y.
        • Huang M.Z.
        • Liu F.Y.
        • et al.
        Absence of DICER1, CTCF, RPL22, DNMT3A, TRRAP, IDH1 and IDH2 hotspot mutations in patients with various subtypes of ovarian carcinomas.
        Biomed Rep. 2015; 3: 33-37
        • Schultz K.A.
        • Yang J.
        • Doros L.
        • et al.
        DICER1-pleuropulmonary blastoma familial tumor predisposition syndrome: a unique constellation of neoplastic conditions.
        Pathol Case Rev. 2014; 19: 90-100
        • Slade I.
        • Bacchelli C.
        • Davies H.
        • et al.
        DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome.
        J Med Genet. 2011; 48: 273-278
        • Bouchard-Fortier G.
        • Kim R.H.
        • Allen L.
        • et al.
        Fertility-sparing surgery for the management of young women with embryonal rhabdomyosarcoma of the cervix: a case series.
        Gynecol Oncol Rep. 2016; 18: 4-7
        • Brand E.
        • Berek J.S.
        • Nieberg R.K.
        • et al.
        Rhabdomyosarcoma of the uterine cervix. Sarcoma botryoides.
        Cancer. 1987; 60: 1552-1560
        • Dehner L.P.
        • Jarzembowski J.A.
        • Hill D.A.
        Embryonal rhabdomyosarcoma of the uterine cervix: a report of 14 cases and a discussion of its unusual clinicopathological associations.
        Mod Pathol. 2012; 25: 602-614
        • Montag T.W.
        • D'Ablaing G.
        • Schlaerth J.B.
        • et al.
        Embryonal rhabdomyosarcoma of the uterine corpus and cervix.
        Gynecol Oncol. 1986; 25: 171-194
        • Li R.F.
        • Gupta M.
        • McCluggage W.G.
        • et al.
        Embryonal rhabdomyosarcoma (botryoid type) of the uterine corpus and cervix in adult women: report of a case series and review of the literature.
        Am J Surg Pathol. 2013; 37: 344-355
        • Riedlinger W.F.
        • Kozakewich H.P.
        • Vargas S.O.
        Myogenic markers in the evaluation of embryonal botryoid rhabdomyosarcoma of the female genital tract.
        Pediatr Dev Pathol. 2005; 8: 427-434
        • Foulkes W.D.
        • Kamihara J.
        • Evans D.G.R.
        • et al.
        Cancer surveillance in Gorlin syndrome and rhabdoid tumor predisposition syndrome.
        Clin Cancer Res. 2017; 23: e62-e67
        • Sredni S.T.
        • Tomita T.
        Rhabdoid tumor predisposition syndrome.
        Pediatr Dev Pathol. 2015; 18: 49-58
        • Kadoch C.
        • Crabtree G.R.
        Mammalian SWI/SNF chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics.
        Sci Adv. 2015; 1e1500447
        • Masliah-Planchon J.
        • Bieche I.
        • Guinebretiere J.M.
        • et al.
        SWI/SNF chromatin remodeling and human malignancies.
        Annu Rev Pathol. 2015; 10: 145-171
        • Biegel J.A.
        • Busse T.M.
        • Weissman B.E.
        SWI/SNF chromatin remodeling complexes and cancer.
        Am J Med Genet C Semin Med Genet. 2014; 166C: 350-366
        • Hasselblatt M.
        • Nagel I.
        • Oyen F.
        • et al.
        SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis.
        Acta Neuropathol. 2014; 128: 453-456
        • Schneppenheim R.
        • Fruhwald M.C.
        • Gesk S.
        • et al.
        Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome.
        Am J Hum Genet. 2010; 86: 279-284
        • Scully R.E.
        Atlas of Tumor Pathology.
        Armed Forces Institute of Pathology, Washington DC1979
        • Young R.H.
        • Oliva E.
        • Scully R.E.
        Small cell carcinoma of the ovary, hypercalcemic type: a clinicopathological analysis of 150 cases.
        Am J Surg Pathol. 1994; 18: 1102-1116
        • Witkowski L.
        • Goudie C.
        • Ramos P.
        • et al.
        The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.
        Gynecol Oncol. 2016; 141: 454-460
        • Jelinic P.
        • Mueller J.J.
        • Olvera N.
        • et al.
        Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
        Nat Genet. 2014; 46: 424-426
        • Kupryjanczyk J.
        • Dansonka-Mieszkowska A.
        • Moes-Sosnowska J.
        • et al.
        Ovarian small cell carcinoma of hypercalcemic type - evidence of germline origin and smarca4 gene inactivation. a pilot study.
        Pol J Pathol. 2013; 64: 238-246
        • Ramos P.
        • Karnezis A.N.
        • Craig D.W.
        • et al.
        Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4.
        Nat Genet. 2014; 46: 427-429
        • Witkowski L.
        • Carrot-Zhang J.
        • Albrecht S.
        • et al.
        Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.
        Nat Genet. 2014; 46: 438-443
        • McCluggage W.G.
        • Witkowski L.
        • Clarke B.A.
        • et al.
        Clinical, morphological and immunohistochemical evidence that small-cell carcinoma of the ovary of hypercalcaemic type (SCCOHT) may be a primitive germ-cell neoplasm.
        Histopathology. 2017; 70: 1147-1154
        • Clarke B.A.
        • Witkowski L.
        • Ton Nu T.N.
        • et al.
        Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics.
        Histopathology. 2016; 69: 727-738
        • Conlon N.
        • Silva A.
        • Guerra E.
        • et al.
        Loss of SMARCA4 expression is both sensitive and specific for the diagnosis of small cell carcinoma of ovary, hypercalcemic type.
        Am J Surg Pathol. 2016; 40: 395-403
        • Jelinic P.
        • Schlappe B.A.
        • Conlon N.
        • et al.
        Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type.
        Mod Pathol. 2016; 29: 60-66
        • Karanian-Philippe M.
        • Velasco V.
        • Longy M.
        • et al.
        SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomas.
        Am J Surg Pathol. 2015; 39: 1197-1205
        • Karnezis A.N.
        • Wang Y.
        • Ramos P.
        • et al.
        Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
        J Pathol. 2016; 238: 389-400
        • Carlson J.W.
        • Nucci M.R.
        • Brodsky J.
        • et al.
        Biomarker-assisted diagnosis of ovarian, cervical and pulmonary small cell carcinomas: the role of TTF-1, WT-1 and HPV analysis.
        Histopathology. 2007; 51: 305-312
        • McCluggage W.G.
        • Oliva E.
        • Connolly L.E.
        • et al.
        An immunohistochemical analysis of ovarian small cell carcinoma of hypercalcemic type.
        Int J Gynecol Pathol. 2004; 23: 330-336
        • Cao D.
        • Guo S.
        • Allan R.W.
        • et al.
        SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma.
        Am J Surg Pathol. 2009; 33: 894-904
        • Karnezis A.N.
        • Hoang L.N.
        • Coatham M.
        • et al.
        Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas.
        Mod Pathol. 2016; 29: 302-314
        • Silva E.G.
        • Deavers M.T.
        • Bodurka D.C.
        • et al.
        Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?.
        Int J Gynecol Pathol. 2006; 25: 52-58
        • Stewart C.J.
        • Crook M.L.
        SWI/SNF complex deficiency and mismatch repair protein expression in undifferentiated and dedifferentiated endometrial carcinoma.
        Pathology. 2015; 47: 439-445
        • Strehl J.D.
        • Wachter D.L.
        • Fiedler J.
        • et al.
        Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant.
        Ann Diagn Pathol. 2015; 19: 198-202
        • Nelen M.R.
        • Padberg G.W.
        • Peeters E.A.
        • et al.
        Localization of the gene for Cowden disease to chromosome 10q22-23.
        Nat Genet. 1996; 13: 114-116
        • Huang J.
        • Kontos C.D.
        PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects.
        J Biol Chem. 2002; 277: 10760-10766
        • Waite K.A.
        • Eng C.
        Protean PTEN: form and function.
        Am J Hum Genet. 2002; 70: 829-844
        • Eng C.
        PTEN hamartoma tumor syndrome.
        in: Pagon R.A. Adam M.P. Ardinger H.H. GeneReviews. University of Washington, Seattle2017
        • Lloyd 2nd, K.M.
        • Dennis M.
        Cowden's disease. A possible new symptom complex with multiple system involvement.
        Ann Intern Med. 1963; 58: 136-142
        • Bubien V.
        • Bonnet F.
        • Brouste V.
        • et al.
        High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.
        J Med Genet. 2013; 50: 255-263
        • Tan M.H.
        • Mester J.L.
        • Ngeow J.
        • et al.
        Lifetime cancer risks in individuals with germline PTEN mutations.
        Clin Cancer Res. 2012; 18: 400-407
        • Baker W.D.
        • Soisson A.P.
        • Dodson M.K.
        Endometrial cancer in a 14-year-old girl with Cowden syndrome: a case report.
        J Obstet Gynaecol Res. 2013; 39: 876-878
        • Edwards J.M.
        • Alsop S.
        • Modesitt S.C.
        Coexisting atypical polypoid adenomyoma and endometrioid endometrial carcinoma in a young woman with Cowden syndrome: case report and implications for screening and prevention.
        Gynecol Oncol Case Rep. 2012; 2: 29-31
        • Elnaggar A.C.
        • Spunt S.L.
        • Smith W.
        • et al.
        Endometrial cancer in a 15-year-old girl: a complication of Cowden syndrome.
        Gynecol Oncol Case Rep. 2012; 3: 18-19
        • Schmeler K.M.
        • Daniels M.S.
        • Brandt A.C.
        • et al.
        Endometrial cancer in an adolescent: a possible manifestation of Cowden syndrome.
        Obstet Gynecol. 2009; 114: 477-479
        • Mahdi H.
        • Mester J.L.
        • Nizialek E.A.
        • et al.
        Germline PTEN, SDHB-D, and KLLN alterations in endometrial cancer patients with Cowden and Cowden-like syndromes: an international, multicenter, prospective study.
        Cancer. 2015; 121: 688-696
        • Djordjevic B.
        • Barkoh B.A.
        • Luthra R.
        • et al.
        Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas.
        Mod Pathol. 2013; 26: 1401-1412
        • Mutter G.L.
        • Lin M.C.
        • Fitzgerald J.T.
        • et al.
        Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.
        J Natl Cancer Inst. 2000; 92: 924-930
        • Black D.
        • Bogomolniy F.
        • Robson M.E.
        • et al.
        Evaluation of germline PTEN mutations in endometrial cancer patients.
        Gynecol Oncol. 2005; 96: 21-24
        • Mester J.
        • Eng C.
        Cowden syndrome: recognizing and managing a not-so-rare hereditary cancer syndrome.
        J Surg Oncol. 2015; 111: 125-130
        • Hahn H.
        • Wicking C.
        • Zaphiropoulous P.G.
        • et al.
        Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome.
        Cell. 1996; 85: 841-851
        • Johnson R.L.
        • Rothman A.L.
        • Xie J.
        • et al.
        Human homolog of patched, a candidate gene for the basal cell nevus syndrome.
        Science. 1996; 272: 1668-1671
        • Gorlin R.J.
        Nevoid basal cell carcinoma (Gorlin) syndrome.
        Genet Med. 2004; 6: 530-539
        • Gorlin R.J.
        • Vickers R.A.
        • Kellen E.
        • et al.
        Multiple basal-cell nevi syndrome. An analysis of a syndrome consisting of multiple nevoid basal-cell carcinoma, jaw cysts, skeletal anomalies, medulloblastoma, and hyporesponsiveness to parathormone.
        Cancer. 1965; 18: 89-104
        • Kimonis V.E.
        • Goldstein A.M.
        • Pastakia B.
        • et al.
        Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome.
        Am J Med Genet. 1997; 69: 299-308
        • Johnson A.D.
        • Hebert A.A.
        • Esterly N.B.
        Nevoid basal cell carcinoma syndrome: bilateral ovarian fibromas in a 3 1/2-year-old girl.
        J Am Acad Dermatol. 1986; 14: 371-374
        • Scully R.E.
        • Galdabini J.J.
        • McNeely B.U.
        Case records of the Massachusetts general hospital. Weekly clinicopathological exercises. Case 14-1976.
        N Engl J Med. 1976; 294: 772-777
        • Rednam S.P.
        • Erez A.
        • Druker H.
        • et al.
        Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood.
        Clin Cancer Res. 2017; 23: e68-75
        • Hippel E.V.
        Ueber eine sehr seltene erkrankung der netzhaut.
        Graefes Arch Ophthalmol. 1904; 59: 83-106
        • Lindau A.
        Zur frage der angiomatosis retinae und ihrer hirnkomplikationen.
        Acta Ophthalmol. 1926; 4: 193-226
        • Poulsen M.L.M.
        • Budtz-Jørgensen E.
        • Bisgaard M.
        Surveillance in von Hippel-Lindau disease (vHL).
        Clin Genet. 2010; 77: 49-59
        • Gersell D.J.
        • King T.C.
        Papillary cystadenoma of the mesosalpinx in von Hippel-Lindau disease.
        Am J Surg Pathol. 1988; 12: 145-149
        • Aydin H.
        • Young R.H.
        • Ronnett B.M.
        • et al.
        Clear cell papillary cystadenoma of the epididymis and mesosalpinx: immunohistochemical differentiation from metastatic clear cell renal cell carcinoma.
        Am J Surg Pathol. 2005; 29: 520-523
        • Brady A.
        • Nayar A.
        • Cross P.
        • et al.
        A detailed immunohistochemical analysis of 2 cases of papillary cystadenoma of the broad ligament: an extremely rare neoplasm characteristic of patients with von Hippel-Lindau disease.
        Int J Gynecol Pathol. 2012; 31: 133-140
        • Nogales F.F.
        • Goyenaga P.
        • Preda O.
        • et al.
        An analysis of five clear cell papillary cystadenomas of mesosalpinx and broad ligament: four associated with von Hippel-Lindau disease and one aggressive sporadic type.
        Histopathology. 2012; 60: 748-757
        • Cox R.
        • Vang R.
        • Epstein J.I.
        Papillary cystadenoma of the epididymis and broad ligament: morphologic and immunohistochemical overlap with clear cell papillary renal cell carcinoma.
        Am J Surg Pathol. 2014; 38: 713-718